Joanne Stevens
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Sleep and Wakefulness Research, Sleep and related disorders, Circadian rhythm and melatonin, Photochromic and Fluorescence Chemistry, Neurotransmitter Receptor Influence on Behavior
Most-Cited Works
- → Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist(2011)270 cited
- → Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial(2020)181 cited
- → Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia(2011)123 cited
- → Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties(2012)121 cited
- → The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold(2013)94 cited
- → Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition(2013)89 cited
- → Critical Developmental Periods for Effects on Male Rat Genitalia Induced by Finasteride, a 5α-Reductase Inhibitor(1993)88 cited
- → Safety pharmacology investigations on the nervous system: An industry survey(2016)85 cited
- → Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man(2016)80 cited
- → Discovery of 5′′‐Chloro‐N‐[(5,6‐dimethoxypyridin‐2‐yl)methyl]‐2,2′:5′,3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia(2013)67 cited